Canada Anti-Hypertensive Drugs Market is anticipated to register a substantial rise over the forecast period, thanks to
For instance, in 2021, 25% of the Canada population under (50-64 year age people) were suffering from hypertension.
According to a report by the Canadian Chronic Disease Surveillance System, hypertension affects approximately 7.4 million adults in Canada, which is equivalent to 21.6% of the adult population. The prevalence of hypertension increases with age, with approximately 60% of Canadians over the age of 60 being affected by hypertension.
Aging Population
Additionally, older adults are more likely to have a higher income, making them more willing and able to pay for prescription medications.
According to a report by the Canadian Institute for Health Information (CIHI), anti-hypertensive drugs were the second most commonly prescribed medication class in Canada in 2019, accounting for 12% of all prescriptions.
Increased Healthcare Spending
Moreover, increased healthcare spending has also led to the development of more sophisticated healthcare infrastructure, such as hospitals and clinics, which are better equipped to diagnose and treat hypertension. This has led to an increase in the number of people seeking medical help for this medical condition, aiding the market.
Download Free Sample ReportRise in Lifestyle Diseases
Additionally, the rising awareness about the importance of managing hypertension and lifestyle diseases has led to an increase in the number of people seeking medical help for their condition. This has contributed to the growth of the market, as more people are being diagnosed with hypertension and prescribed anti-hypertensive drugs.
Development of Novel Drugs
Another recent development in the market is the increasing usage of telemedicine for the management of hypertension. Telemedicine allows patients to consult with their healthcare provider remotely, which can improve access to care for patients who may have difficulty traveling to a clinic or hospital. Telemedicine can also be a more convenient option for patients and may reduce the burden on healthcare providers. As a result, many healthcare providers are taking up telemedicine to manage hypertension, and this trend is expected to continue to grow in the coming years.
Increased Awareness of Hypertension
In addition to this, the increased awareness of hypertension has led to a greater emphasis on lifestyle modifications, such as exercise and a healthy diet, to manage the condition. This has led to an increase in the number of people taking a proactive approach to managing their hypertension, which has contributed to the growth of the market.
Furthermore, the rise in awareness among consumers regarding hypertension has also led to more research into the condition and the development of new and more effective treatment options. This has helped to stimulate innovation in the Canada anti-hypertensive drugs market and contributed to the development of new drugs.
Recent Developments
- Entresto(sacubitril/valsartan) - This drug was approved by Health Canada in 2019 forthe treatment of heart failure with reduced ejection fraction. It is acombination of two drugs that work together to improve the heart's ability topump blood and reduce the risk of hospitalization due to heart failure.
- QternmetXR (dapagliflozin/saxagliptin/metformin hydrochloride) - This drug was launchedin Canada in 2020 for the treatment of type 2 diabetes and hypertension. Itcombines three drugs in one tablet to help control blood sugar levels and lowerblood pressure.
- Mylan-TelmisartanHCTZ (telmisartan/hydrochlorothiazide) - This drug was launched in Canada in2021 to treat hypertension. It is a combination of two drugs that work togetherto lower blood pressure and reduce the risk of heart attack and stroke.
Market Segmentation
Market Players
Pfizer Canada Inc., Merck Canada Inc., AstraZeneca Canada Inc, Novartis Pharmaceuticals Canada Inc, Sanofi-Aventis Canada Inc., Boehringer Ingelheim (Canada) Ltd., Bristol-Myers Squibb Canada., Takeda Canada Inc., Teva Canada Ltd., and Servier Canada Inc. are some of the leading players operating in the Canada anti-hypertensive drugs market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume in Units, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | By Therapeutic Class By Type By Distribution Channel By Region |
| Regional Scope | Ontario region; Quebec region; Alberta region; British Columbia region; Saskatchewan and Manitoba region; Rest of Canada |
| Key Companies Profiled | Pfizer Canada Inc., Merck Canada Inc., AstraZeneca Canada Inc, Novartis Pharmaceuticals Canada Inc, Sanofi-Aventis Canada Inc., Boehringer Ingelheim (Canada) Ltd., Bristol-Myers Squibb Canada., Takeda Canada Inc., Teva Canada Ltd., Servier Canada Inc. |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
